Mr. Williams just accused you of fear-mongering over this whole issue. It seems to me we are talking about serious issues--a national pharmaceutical strategy, national pharmacare--all of which are hampered by the lack of movement with respect to cheaper generic drugs getting onto the market.
Could you give us some sense of the impact of these regulatory changes that are being proposed?